Sunitinib Versus Placebo for Patients With Advanced Renal Cell Carcinoma: Final Overall Survival Results of a Phase III Randomized Trial
A phase III randomized trial comparing sunitinib versus placebo in the treatment of advanced renal cell carcinoma has concluded that sunitinib can significantly improve overall survival rates in these patients. Sunitinib is a type of targeted therapy that blocks the growth of blood vessels that supply tumors, thereby slowing or stopping tumor growth. The study enrolled 750 patients with advanced renal cell carcinoma who had not previously received chemotherapy. Participants were randomly assigned to receive either sunitinib or a placebo. The results showed that the median overall survival was 26.4 months for patients treated with sunitinib, compared to 21.8 months for those who received a placebo. The findings confirm the clinical benefits of sunitinib in treating advanced renal cell carcinoma and support its continued use as a standard therapy for these patients.